<DOC>
	<DOC>NCT02660944</DOC>
	<brief_summary>This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus.</brief_summary>
	<brief_title>A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>CLASI score greater than or equal to 10 at Baseline Positive for one or more RNA autoantibodies 1. severe, active central nervous system (CNS) involvement at Screening; 2. severe renal involvement at Screening (urine protein/creatinine ratio of &gt;200 mg/mmol, or an estimated creatinine clearance of &lt;30 mL/min); 3. use of cyclophosphamide within 3 months of the Baseline visit; 4. use of rituximab within 6 months of the Baseline visit; 5. use of belimumab within 3 months of the Baseline visit; 6. use of background medications within 1 month of Baseline in excess of: i. mycophenolate mofetil &gt; 3 g/day; ii. azathioprine &gt; 200 mg/day; iii. methotrexate &gt; 25 mg/day; iv. hydroxychloroquine &gt; 400 mg/day; v. prednisone (or equivalent) &gt; 15 mg/day; 7. use of an intravenous steroid "pulse" within 2 months of Baseline; 8. use of an intramuscular steroid injection within 1 month of Baseline; 9. change in SLE medications within 1 month of Baseline; 10. the presence of a clinically significant infection in the judgement of the Investigator within seven days prior to the receipt of the first dose of study drug; 11. positive viral load test for hepatitis B, C, or HIV at Screening; 12. participation in another clinical trial with receipt of an investigational product within 3 months or 5 half lives, of last administration (whichever is longer) from Baseline; 13. positive pregnancy test at Screening or at Baseline; 14. female subjects currently breast feeding at Baseline; 15. inability or unwillingness to comply with protocolspecified procedures which, in the opinion of the Investigator, would make the subject unsuitable for study participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>